The effect of the number of hepatic inflow occlusion times on the prognosis of ruptured hepatocellular carcinoma patients after hepatectomy

Feng Xia¹, Zhiyuan Huang¹, Elijah Ndhlovu¹, Mingyu Zhang², Xiaoping Chen¹, Bixiang Zhang¹ and Peng Zhu¹*

Abstract

Background and aim: It has been previously reported that inflow occlusion does not affect postoperative outcomes in hepatocellular carcinoma patients. However, for patients with ruptured hepatocellular carcinoma (rHCC), the effect of hepatic inflow occlusion and the number of occlusion times on the prognosis is unknown.

Methods: 203 patients with ruptured hepatocellular carcinoma were enrolled in this study. They were first divided into the non-hepatic inflow occlusion (non-HIO) group and the hepatic inflow occlusion (HIO) group. The Kaplan–Meier method was used to compare the recurrence-free survival and overall survival between the two groups. Patients in the HIO group were further divided into one-time HIO and two times HIO groups. KM method was also used to compare the two groups. Finally, independent risk factors affecting RFS and OS were determined by multivariate Cox regression analysis.

Result: In the non-HIO group, 1-, 3- and 5-year OS rates were 67.0%, 41.0%, and 22.0% respectively, and RFS rates were 45.0%, 31.0%, and 20.0% respectively; In the one-HIO group, the 1-, 3-, and 5-year OS rates were 55.1%, 32.1%, and 19.2% respectively, and RFS rates were 33.3%, 16.7%, and 7.7% respectively; In the two-HIO group, 1-, 3-, and 5-year OS rates were 24.0%, 0.0%, and 0.0% respectively, and RFS rates were 8.0%, 0.0%, and 0.0% respectively. By Cox regression analysis, HIO was an independent risk factor for a poor prognosis in rHCC patients.

Conclusion: One time hepatic inflow occlusion did not affect postoperative OS, but negatively affected the RFS of rHCC patients; two times hepatic inflow occlusion negatively affected the postoperative OS and RFS in patients with rHCC.

Keywords: Ruptured hepatocellular carcinoma, Hepatic inflow occlusion, Hepatectomy

Introduction

Hepatocellular carcinoma (HCC) is one of the most serious cancers in the world and the second leading cause of death due to cancer. Rupture of hepatocellular carcinoma (HCC) is a rare and serious complication of HCC [1–5]. In recent years, the number of ruptured HCC (rHCC) patients has been increasing year by year, especially in Asia, and the proportion of rupture is much higher than in Europe and the United States. For patients with rHCC, transcatheter arterial chemoembolization (TACE), intra-peritoneal chemotherapy, and hepatectomy have been used, but recent studies have shown that two-stage delayed hepatectomy is a relatively better treatment for...
suitable patients [6, 7]. Although rHCC patients have a good prognosis after hepatectomy, there is still a need to pay attention to their situation because ruptured HCC patients are prone to hemodynamic instability.

Since intraoperative bleeding is the main problem in hepatectomy, and intraoperative blood transfusion may affect the postoperative prognosis of patients, researchers have introduced the method of hepatic blood flow occlusion to control bleeding. At present, the most widely used techniques are the Pringle Maneuver and Hemihepatic inflow occlusion [8, 9]. The Pringle maneuver was first described in 1908 as a method that blocks hilar vessels and achieves the effect of controlling hepatic blood flow by clamping the hepatoduodenal ligament; in 1987, a hemihepatic occlusion (HHO) technique was proposed to control hepatic blood flow [10]. In short, both methods can effectively control hepatic blood flow, but they inevitably cause hepatic hypoperfusion and ischemia–reperfusion injury, and liver dysfunction occurs at the same time [11–13]. Patients with ruptured HCC are hemodynamically unstable on admission, and most of them have associated cirrhosis, reducing their tolerance to ischemia. Therefore, hepatic inflow occlusion can affect the liver function of the residual liver after surgery, and it may also affect the long-term prognosis of rHCC patients after surgery.

In the past, Jing-Hang Jiang et al. [14] believed that hepatic inflow occlusion did not affect the postoperative outcomes of HCC patients, while other researchers [15] found that HIO affected postoperative liver function, which in turn made the postoperative prognosis worse. However, the long-term effects of HIO on the prognosis of patients with ruptured HCC are unknown, and the effect of the number of times of HIO on prognosis is also unclear.

In this retrospective study, we aimed to assess the prognostic impact of HIO in patients with ruptured HCC. We also compared the effect of the number of HIO on the overall survival and recurrence-free survival of patients.

Methods

Patients
We retrospectively collected the data of 203 patients who were diagnosed with ruptured HCC and received surgical treatment at Wuhan Tongji Hospital between January 2010 and December 2018. We followed strict inclusion and exclusion criteria; the inclusion criteria were: (1) ruptured liver cancer determined by both contrast-enhanced CT and MRI (2) postoperative diagnosis of HCC confirmed by an experienced pathologist (3) liver function classification in Child–Pugh class A or B (4) no invasion of the great vessels of the liver (5) negative resection margin (6) this admission was the first discovery of tumors; the exclusion criteria were: (1) postoperative diagnosis was not HCC (2) patients who had developed metastasis (3) patients who died within one month after surgery. Our research was authorized by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (TJ-IRB20210205) [2021/02/04], and all patients gave informed consent.

Propensity score matching analysis
Retrospective studies are prone to selection bias or confounding bias. Therefore, we used propensity score matching to reduce the selected bias. In this study, for patients undergoing hepatic inflow occlusion (HIO), there were differences in one variable. We included the BCLC stage in the propensity score model to balance the baseline. We performed 1:1 matching using SPSS 25.0. We chose a 0.1 caliper width so that an optimal trade-off can be obtained.

Treatment mode
All patients included in the study were operated on by experienced surgeons at our liver surgery center. Whether hepatic inflow occlusion was to be performed was determined by the surgeon according to the intraoperative conditions, the extent of the tumor, and liver fibrosis or cirrhosis [16]. The Pringle Maneuver or hemihepatic vascular occlusion methods were chosen on a case-by-case basis in the HIO group. For these two methods, the time of each blocking was strictly limited to about 15 min, and the release interval was 5 min. Both HIO methods aim to reduce bleeding during parenchymal transection.

Classification of postoperative complications
Because of the wide variety of complications and the relatively small number of patients with complications in each category, we used the Clavien-Dindo complication classification [17].

Follow-up
All patients were followed up every 3 months within the first year and every six months after the second year after discharge, and all examinations included laboratory tests such as liver function, renal function, routine blood tests, tumor markers, and imaging tests such as enhanced abdominal CT and MRI. The time from the first day after operation to death or the last follow-up was defined as the overall survival (OS) rate, and the time from the first day after operation to the discovery of new lesions by physical and clinical examinations or the last follow-up was defined as the recurrence-free survival (RFS) rate. We set the time of the last follow-up to July 30, 2021.
Data analysis
Continuous variables conforming to normal distribution are expressed by (mean ± standard deviation), and continuous variables not conforming to normal distribution are expressed by median (range). The differences between the two groups were compared using the independent samples t-test and Mann–Whitney U test, respectively, and the categorical data were analyzed using a fourfold table and a chi-square test. OS and RFS were calculated using the Kaplan–Meier method, and risk factors for OS

| Variables                      | Non-hepatic inflow occlusion | Hepatic inflow occlusion | p-value |
|-------------------------------|------------------------------|--------------------------|---------|
|                               | n = 100                      | n = 103                  |         |
| Gender (%)                    |                              |                          | 0.104   |
| Male                          | 85 (85.0)                    | 95 (92.2)                |         |
| Female                        | 15 (15.0)                    | 8 (7.8)                  |         |
| Age (y)                       | 43.9 ± 11.7                  | 42.8 ± 11.4              | 0.498   |
| Length (%)                    |                              |                          | 0.437   |
| ≤ 5 cm                        | 26 (26.0)                    | 22 (21.4)                |         |
| > 5 cm                        | 74 (74.0)                    | 81 (78.6)                |         |
| Tumor number (%)              |                              |                          | 0.397   |
| Single                        | 81 (81.0)                    | 78 (75.7)                |         |
| Multiple                      | 19 (19.0)                    | 25 (24.3)                |         |
| BCLC stage (%)                |                              |                          | 0.009   |
| A                             | 67 (67.0)                    | 49 (47.6)                |         |
| B                             | 20 (20.0)                    | 25 (24.3)                |         |
| C                             | 13 (13.0)                    | 29 (28.2)                |         |
| Child–Pugh (%)                |                              |                          | 0.219   |
| A                             | 84 (84.0)                    | 79 (76.7)                |         |
| B                             | 16 (16.0)                    | 24 (23.3)                |         |
| AFP (%)                       |                              |                          | 0.470   |
| ≤ 400 ng/ml                   | 39 (39.0)                    | 35 (34.0)                |         |
| > 400 ng/ml                   | 61 (61.0)                    | 68 (66.0)                |         |
| Edmondson-steiner (%)         |                              |                          | 0.057   |
| I                             | 13 (13.0)                    | 8 (7.8)                  |         |
| II                            | 36 (36.0)                    | 54 (52.4)                |         |
| III                           | 33 (33.0)                    | 21 (20.4)                |         |
| IV                            | 18 (18.0)                    | 20 (19.4)                |         |
| Necrosis (%)                  |                              |                          | 0.086   |
| No                            | 68 (68.0)                    | 81 (78.6)                |         |
| Yes                           | 32 (32.0)                    | 22 (21.4)                |         |
| Local invasion (%)            |                              |                          | 0.437   |
| No                            | 46 (46.0)                    | 53 (51.5)                |         |
| Yes                           | 54 (54.0)                    | 50 (48.5)                |         |
| ALB (g/L)                     | 35.2 (32.3–38.6)             | 35.9 (33.1–38.8)         | 0.516   |
| ALT (U/L)                     | 27.0 (21.0–41.0)             | 28.0 (21.0–41.0)         | 0.548   |
| AST (U/L)                     | 36.5 (28.0–61.3)             | 37.0 (24.0–66.0)         | 0.919   |
| ALP (U/L)                     | 76.0 (56.0–93.0)             | 75.0 (61.0–93.0)         | 0.223   |
| GGT (U/L)                     | 47.0 (28.3–91.0)             | 58.0 (36.0–129.0)        | 0.074   |
| HBsAg (%)                     |                              |                          | 0.078   |
| No                            | 17 (17.0)                    | 9 (8.7)                  |         |
| Yes                           | 83 (83.0)                    | 94 (91.3)                |         |

BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
and RFS were screened out by univariate and multivariate Cox regression. SPSS 25.0 statistical software and R (version 4.0.5, R Foundation for Statistical Computing, Vienna, Austria) were used for data processing.

### Results

Basic characteristics of patients in the hepatic inflow occlusion (HIO) and non-HIO groups (before and after PSM)

A total of 203 patients with ruptured HCC were enrolled. The baseline data are shown in Table 1. We included

| Variables                  | Non-hepatic inflow occlusion n = 80 | Hepatic inflow occlusion n = 80 | p-value |
|----------------------------|-------------------------------------|---------------------------------|---------|
| Gender (%)                 |                                     |                                 | 0.175   |
| Male                       | 65 (81.3)                           | 72 (90.0)                       |         |
| Female                     | 15 (18.7)                           | 8 (10.0)                        |         |
| Age (y)                    | 45.6 ± 11.4                         | 44.4 ± 11.3                     | 0.568   |
| Length (%)                 |                                     |                                 | 0.858   |
| ≤ 5 cm                     | 21 (26.3)                           | 22 (27.5)                       |         |
| > 5 cm                     | 59 (73.8)                           | 58 (72.5)                       |         |
| Tumor number (%)           |                                     |                                 | 0.855   |
| Single                     | 61 (76.3)                           | 59 (73.8)                       |         |
| Multiple                   | 19 (23.8)                           | 21 (26.3)                       |         |
| BCLC stage (%)             |                                     |                                 | 1.000   |
| A                          | 48 (60.0)                           | 48 (60.0)                       |         |
| B                          | 20 (25.0)                           | 20 (25.0)                       |         |
| C                          | 12 (15.0)                           | 12 (15.0)                       |         |
| Child-Pugh (%)             |                                     |                                 | 0.454   |
| A                          | 64 (80.0)                           | 59 (73.8)                       |         |
| B                          | 16 (20.0)                           | 21 (26.3)                       |         |
| AFP (%)                    |                                     |                                 | 0.748   |
| ≤ 400 ng/ml                | 31 (38.8)                           | 34 (42.5)                       |         |
| > 400 ng/ml                | 49 (61.3)                           | 46 (57.5)                       |         |
| Edmondson-steiner (%)      |                                     |                                 | 0.091   |
| I                          | 11 (13.8)                           | 7 (8.8)                         |         |
| II                         | 28 (35.0)                           | 43 (53.8)                       |         |
| III                        | 26 (32.5)                           | 16 (20.0)                       |         |
| IV                         | 15 (18.8)                           | 14 (17.5)                       |         |
| Necrosis (%)               |                                     |                                 | 0.205   |
| No                         | 56 (70.0)                           | 63 (78.8)                       |         |
| Yes                        | 24 (30.0)                           | 17 (21.3)                       |         |
| Local invasion (%)         |                                     |                                 | 0.635   |
| No                         | 36 (45.0)                           | 40 (50.0)                       |         |
| Yes                        | 44 (55.0)                           | 40 (50.0)                       |         |
| ALB (g/L)                  | 35.3 (32.3–38.1)                    | 35.6 (32.9–37.8)                | 0.889   |
| ALT (U/L)                  | 27.0 (21.0–43.3)                    | 30.5 (24.0–44.0)                | 0.321   |
| AST (U/L)                  | 37.5 (28.5–63.5)                    | 35.0 (22.3–65.8)                | 0.512   |
| ALP (U/L)                  | 76.0 (54.5–94.5)                    | 76.5 (61.0–91.0)                | 0.475   |
| GGT (U/L)                  | 49.5 (28.0–93.3)                    | 51.5 (35.0–126.8)               | 0.280   |
| HBsAg (%)                  |                                     |                                 | 0.159   |
| No                         | 14 (17.5)                           | 7 (8.8)                         |         |
| Yes                        | 66 (82.5)                           | 73 (91.3)                       |         |

BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion; PSM, Propensity Score Matching.
gender, age, tumor length, tumor number, BCLC stage, Child–Pugh classification of liver function, alpha-feto-protein (AFP), Edmondson-Steiner classification, tumor necrosis, local tumor invasion, preoperative albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), glutamyl transferase (GGT), HBsAg and other variables. Only the difference in the BCLC stage \( (P = 0.009) \) between the two groups was of statistical significance. The mean age of patients in the HIO group was 42.8 \( \pm \) 11.4 years and 92.2% were male; the mean age of patients in the non-HIO group was 43.9 \( \pm \) 11.7 years and 85.0% were male. Nearly 90% of all patients were HBsAg positive (Table 1).

After 1:1 PSM correction, all variables in the non-HIO group were balanced, and the BCLC stage was not statistically different between the two groups \( (P = 1.000) \) (Table 2).

### Intraoperative and postoperative clinical results
In the non-HIO group, the average blood loss was 441 ± 183.5 ml, the average operation time was 321 ± 133.7 min, 41 patients had postoperative complications; in the HIO group, the average blood loss was 498.2 ± 258.3 ml, the average operation time was 305.4 ± 121.8 min, 36 patients had postoperative complications. There was no statistical difference in blood loss, operation time, and postoperative complications between the non-HIO group and the HIO group (Table 3).

### Comparison of the OS and RFS in the HIO and non-HIO groups
In the HIO group, the median survival time was 358.0 days, the 1-, 3-, and 5-year OS rates were 47.6%, 24.2%, and 14.6% respectively; the 1-, 3-, and 5-year RFS rates were 27.2%, 12.6%, and 5.8% respectively; In the non-HIO group, the median survival time was 730 days, the 1-, 3-, and 5-year OS rates were 67.0%, 41.0%, and 22.0% respectively; the 1-, 3-, and 5-year RFS rates were 45.0%, 31.0%, and 20.0% respectively.

Survival curves were plotted by the K-M method, and the OS \( (P = 0.007, HR = 1.52 (1.12–2.05)) \) and RFS \( (P = 0.001; HR = 1.82 (1.33–2.49)) \) were statistically different between the two groups (Fig. 1A and B). After PSM, survival curves were plotted by the K-M method, and the OS \( (P = 0.038, HR = 1.43 (1.02–2.02)) \) and RFS \( (P = 0.005; HR = 1.65 (1.17–2.33)) \) were also statistically different between the two groups (Fig. 1C and D).

### Basic characteristics of the patients in the one-time hepatic inflow occlusion group(one-HIO) and the two-times hepatic inflow occlusion group(two-HIO)
The HIO group was subdivided into the one-time HIO group \( (n = 78) \) and the two-times HIO group \( (n = 25) \). The included variables were the same as above. There was no statistical difference in all variables between the two groups \( (P > 0.05) \) (Table 4).
Comparison of the OS and RFS in the one-HIO and two-HIO groups

In the one-HIO group, the median survival time was 469.3 days, the 1-, 3-, and 5-year OS rates were 55.1%, 32.1%, and 19.2% respectively; the 1-, 3-, and 5-year RFS rates were 33.3%, 16.7%, and 7.7% respectively; In the two-HIO group, the median survival time was 257.7 days, the 1-, 3-, and 5-year OS rates were 24.0%, 0.0%, and 0.0% respectively; the 1-, 3-, and 5-year RFS rates were 8.0%, 0.0%, and 0.0% respectively.

We plotted the survival curves using the K-M method, and the OS (P < 0.001, HR = 2.69 (1.63–4.44)) and RFS (P = 0.025, HR = 1.78 (1.07–2.96)) were statistically different between these two groups (Fig. 2).

The one-HIO group and two-HIO group were compared with the non-HIO group for OS and RFS, respectively

According to the survival curve, when the one-HIO and the non-HIO group were compared, there was no statistical difference in OS (P = 0.088) between the two groups, and there was a difference in RFS (P = 0.003 HR = 1.63 (1.18–2.27)) between the two groups (Fig. 2); when the two-HIO and the non-HIO groups were compared, both the OS (P < 0.001, HR = 3.64 (2.21–5.99)) and the RFS (P < 0.001 HR = 2.67 (1.61–4.43)) were statistically different between the two groups (Fig. 2).
The impact of HIO on the prognosis of ruptured HCC patients was determined using Cox regression

To further determine the effect of HIO and the number of times of HIO on the postoperative prognosis of ruptured HCC patients, we used a multivariate Cox regression model to determine the risk factors affecting the postoperative OS and RFS of ruptured HCC patients.

In all 203 patients, we identified risk factors affecting OS and RFS by univariate and multivariate Cox regression models. In terms of the overall survival, HIO (P < 0.001) was a risk factor for decreased OS, but after stratifying for the number of occlusion times, one-HIO was not a risk factor for decreased OS (P = 0.495), and two-HIO was a risk factor for decreased OS (P < 0.001, HR = 4.116 (2.398–7.065)) (Table 5). For the RFS, not only was HIO (P < 0.001) a risk factor for decreased RFS, but both one-HIO (P = 0.003, HR = 1.643 (1.181–2.285)) and two-HIO (P < 0.001, HR = 2.501 (1.521–4.112)) were also risk factors for decreased RFS (Table 6).

In addition, tumor length, number of tumors, BCLC stage, local invasion, ALB, ALT, AST, and ALP were also independent risk factors affecting OS; and GGT and tumor length were also independent risk factors affecting RFS.

Discussion

Rupture of liver cancer is a rare and serious complication of liver cancer with a high mortality rate. Although there are many treatment methods, such as TACE, intraperitoneal chemotherapy, surgical treatment, conservative treatment, etc., at present, the relatively better treatment is staged hepatectomy (TACE for stage one treatment, followed by surgery as the second stage) [6]. Currently, there is an increasing number of research institutions discussing the risk factors affecting the postoperative survival of patients with ruptured HCC, hoping to find some prognostic factors to better manage rHCC patients [18–20]. In hepatectomy for rHCC patients, we need to pay attention to the amount of bleeding during surgery, because some rHCC patients are inherently hemodynamically unstable. Surgeons usually use hepatic inflow occlusion techniques, including the Pringle Maneuver and hemihepatic vascular occlusion to control the amount of bleeding. By blocking the blood flow into the liver, intraoperative blood loss is greatly reduced and the probability of blood transfusion is also reduced [8, 9, 21–23]. However, the adverse consequences of hepatic inflow occlusion should not be ignored. Both methods can cause postoperative liver function damage, and although some studies have indicated that HIO may not have an effect on the postoperative prognosis of HCC patients, the long-term survival rate of HIO in ruptured HCC patients

| Variables | One time hepatic inflow occlusion n = 78 | Two times hepatic inflow occlusion n = 25 | p-value |
|-----------|----------------------------------------|---------------------------------------|---------|
| Gender (%) |                                        |                                       | 0.077   |
| Male      | 74 (94.9)                              | 21 (84.0)                             |         |
| Female    | 4 (5.1)                                | 4 (16.0)                              |         |
| Age (y) 543.9 ± 11.4 | 39.1 ± 11.0                              | 0.498                                    |
| Length (%) |                                        |                                       | 0.061   |
| ≤ 5 cm   | 20 (25.6)                              | 2 (8.0)                              |         |
| > 5 cm    | 58 (74.4)                              | 23 (92.0)                            |         |
| Tumor number (%) |                                        |                                       | 0.567   |
| Single    | 58 (74.4)                              | 20 (80.0)                            |         |
| Multiple  | 20 (25.6)                              | 5 (20.0)                             |         |
| BCLC stage (%) |                                        |                                       | 0.2     |
| A         | 41 (52.6)                              | 8 (32.0)                             |         |
| B         | 17 (21.8)                              | 8 (32.0)                             |         |
| C         | 20 (25.6)                              | 9 (36.0)                             |         |
| Child–Pugh (%) |                                        |                                       | 0.654   |
| A         | 59 (75.6)                              | 20 (80.0)                            |         |
| B         | 19 (24.4)                              | 5 (20.0)                             |         |
| AFP (%) |                                        |                                       | 0.093   |
| ≤ 400 ng/ml | 31 (39.7)                              | 5 (20.0)                             |         |
| > 400 ng/ml | 47 (60.3)                              | 21 (84.0)                            |         |
| Edmondson-steiner (%) |                                        |                                       | 0.115   |
| I         | 7 (9.0)                                | 1 (4.0)                              |         |
| II        | 45 (57.7)                              | 9 (36.0)                             |         |
| III       | 14 (17.9)                              | 7 (28.0)                             |         |
| IV        | 12 (15.4)                              | 8 (32.0)                             |         |
| Necrosis (%) |                                        |                                       | 0.136   |
| No        | 64 (82.1)                              | 17 (68.0)                            |         |
| Yes       | 14 (17.9)                              | 8 (32.0)                             |         |
| Local invasion (%) |                                        |                                       | 0.188   |
| No        | 43 (55.1)                              | 10 (40.0)                            |         |
| Yes       | 35 (44.9)                              | 15 (60.0)                            |         |
| ALB (g/L) | 35.6 (31.3–38.1)                       | 36.5 (34.3–43.5)                     | 0.053   |
| ALT (U/L) | 27.0 (20.5–41.8)                       | 30.0 (24.0–49.0)                     | 0.636   |
| AST (U/L) | 35.0 (22.0–65.3)                       | 50.0 (31.5–80.0)                     | 0.017   |
| ALP (U/L) | 77.0 (61.0–91.3)                       | 72.0 (61.5–98.0)                     | 0.661   |
| GGT (U/L) | 55.5 (36.0–122.3)                      | 58.0 (29.5–147.5)                    | 0.929   |
| HBsAg (%) |                                        |                                       | 0.881   |
| No        | 7 (9.0)                                | 2 (8.0)                              |         |
| Yes       | 71 (91.0)                              | 23 (92.0)                            |         |

BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
is unknown, and the effect of the number of occlusion times on the prognosis is also unclear.

Previous studies have compared the Pringle Maneuver with hemihepatic blood flow occlusion, and there is still some controversy. In their meta-analysis, Wang et al. [23] found that the effects of the two techniques were not statistically different, but patients who were subjected to hemihepatic inflow occlusion had less liver injury. Similarly, Li et al. [24] and Chau et al. [15] found that hemihepatic inflow occlusion achieved similar results to the Pringle maneuver, but it had the advantage of reduced liver injury and better postoperative liver function recovery. While Yu et al. [25] concluded that the hemihepatic occlusion technique had the advantage of reduced operative time and blood loss, less injury, and better recovery when compared to the Pringle maneuver. In our study, the hepatic inflow occlusion method was selected according to the specific situation of the operator, and the blockage time was about 15 min each time. Although some studies indicated that hemihepatic blood flow blocking once could last for a longer time, considering that most patients had liver cirrhosis, the blockage time was set at about 15 min in our center. For patients with two blockages, the interval between each blockage was about 5 min.

Several previous retrospective studies [26–29] showed that there was no significant difference in postoperative long-term survival between HIO and non-HIO groups in HCC patients. Similarly, a meta-analysis [23] compared the effect of vascular occlusion in liver surgery on postoperative HCC patients, and the results showed that HIO did not affect the postoperative overall survival. In our study, we specifically studied the effect of HIO in ruptured HCC patients after surgery, while further analyzing the effect of the number of blockages on long-term survival. Our results showed that one HIO had no effect on postoperative OS but had a negative effect on RFS in patients with rHCC; Overall, HIO negatively affected both the postoperative OS and the RFS in patients with rHCC, which is different from previous studies on patients with HCC. Ischemia during hepatic portal blood flow occlusion is one of the factors that can negatively affect the overall survival, and ischemia–reperfusion injury (IRI) after occlusion may also harm liver function [30, 31]. However, only one occlusion did not affect the OS in our study, while two occlusions were associated with a reduction in the OS. So the total number of occlusions and the composite effect of multiple ischemia–reperfusion injuries may also differently affect the OS. The main mechanisms through which HIO affects recurrence can also be summed up in two points: (1) ischemia destroys the adhesion between tumor and endothelial cells, resulting in microvascular injury, and reperfusion injury promotes metastasis and growth of tumor cells [32–35]. (2) When in a blocked state, the pressure gradient between tumor vessels and portal vein can trigger cancer cells to detach from the main tumor, allowing tumor cells to translocate and spread.

Another point to note is why have most studies stated that HIO leads to tumor recurrence, while

\[ \text{Fig. 2} \quad \text{Overall survival and Recurrence-free survival curves of ruptured HCC patients in the one-HIO, two-HIO, and non-HIO groups treated by hepatectomy. A represents OS, B represents RFS.} \]
the conclusions for the postoperative OS of patients are very different? Lucinda Shen et al. [36] suggested that when performing HIO, they observed different blood flow responses of hepatic microvessels in different patients, which could also explain the different ischemia–reperfusion injury (IRI) effects on different patients when performing HIO, which in turn may lead to different postoperative OS's. At the same time, it has been confirmed in some studies that changes in the circulation lead to heterogeneity in the response to IRI.

Table 5  Univariate and multivariate analysis to identify factors that predict overall survival in patients with ruptured hepatocellular carcinoma treated by hepatectomy

|                          | Univariate analysis | Multivariate analysis |
|--------------------------|--------------------|-----------------------|
|                          | p      | HR     | 95% confidence interval | p      | HR     | 95% confidence interval |
| Gender                   |        |        |                       |        |        |                       |
| Male/female              | 0.427  | 1.234  | 0.735–2.070           |        |        |                       |
| Age                      | 0.720  | 1.003  | 0.987–1.019           |        |        |                       |
| Tumor length             |        |        |                       |        |        |                       |
| Per cm                   | 0.041  | 1.636  | 1.020–2.626           | 0.013  | 1.691  | 1.119–2.554           |
| Tumor number             |        |        |                       |        |        |                       |
| Multiple/single          | 0.021  | 1.822  | 1.095–3.034           | 0.016  | 1.862  | 1.120–3.096           |
| BCLC                     |        |        |                       |        |        |                       |
| B/A                      | 0.621  | 0.873  | 0.509–1.496           | 0.822  | 0.941  | 0.552–1.603           |
| C/A                      | 0.002  | 2.000  | 1.296–3.087           | 0.003  | 1.880  | 1.239–2.852           |
| Child–Pugh               |        |        |                       |        |        |                       |
| B/A                      | 0.082  | 0.665  | 0.420–1.053           |        |        |                       |
| AFP                      |        |        |                       |        |        |                       |
| > 400 ng/ml/ ≤ 400 ng/ml | 0.071  | 1.452  | 0.969–2.175           |        |        |                       |
| Edmondson-steiner        |        |        |                       |        |        |                       |
| IV/III/II/I              | 0.637  | 1.046  | 0.969–2.175           |        |        |                       |
| Necrosis                 |        |        |                       |        |        |                       |
| Yes/no                   | 0.485  | 0.872  | 0.867–1.263           |        |        |                       |
| Local invasion           |        |        |                       |        |        |                       |
| Yes/no                   | 0.002  | 1.718  | 0.592–1.282           | 0.001  | 1.686  | 1.223–2.323           |
| ALB                      |        |        |                       |        |        |                       |
| Per g                    | 0.005  | 0.957  | 1.226–2.407           | 0.014  | 0.969  | 0.945–0.994           |
| ALT                      |        |        |                       |        |        |                       |
| Per U                    | 0.007  | 0.990  | 0.927–0.987           | <0.001 | 0.987  | 0.980–0.994           |
| AST                      |        |        |                       |        |        |                       |
| Per U                    | 0.010  | 1.006  | 0.982–0.997           | 0.001  | 1.007  | 1.003–1.011           |
| ALP                      |        |        |                       |        |        |                       |
| Per U                    | 0.024  | 1.002  | 1.001–1.010           | 0.030  | 1.002  | 1.000–1.003           |
| GGT                      |        |        |                       |        |        |                       |
| Per U                    | 0.775  | 1.000  | 0.998–1.002           |        |        |                       |
| HBsAg                    |        |        |                       |        |        |                       |
| Yes/no                   | 0.242  | 0.736  | 0.440–1.230           | <0.001 |        |                       |
| Times of HIO             |        |        |                       |        |        |                       |
| 1/0                      | 0.298  | 1.215  | 0.842–1.752           | 0.495  | 1.130  | 0.795–1.606           |
| 2/0                      | <0.001 | 4.522  | 2.542–8.045           | <0.001 | 4.116  | 2.398–7.065           |
| Blood loss               |        |        |                       |        |        |                       |
| > 400 ml/ ≤ 400 ml       | 0.023  | 1.322  | 1.182–1.744           | 0.144  | 1.288  | 0.892–1.286           |

BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion
and in livers with cirrhosis and fibrosis, the interaction between molecules disrupts the balance between cells and their surrounding matrix and also allows hepatic vascular remodeling. Many cells are involved in this process, including hepatic stellate cells, macrophages, and Kupffer cells. Hepatic endothelial cells are very important and help stabilize blood vessels. It is therefore necessary to develop techniques to perform intraoperative monitoring of hepatic microcirculation during hepatic inflow occlusions in the future [37].

**Table 6** Univariate and multivariate analysis to identify factors that predict recurrence-free survival in patients with ruptured hepatocellular carcinoma treated by hepatectomy

|                  | Univariate analysis |                  | Multivariate analysis |                  |
|------------------|---------------------|------------------|-----------------------|------------------|
|                  | p       | HR | 95% confidence interval | p       | HR | 95% confidence interval |
| Gender           |         |    |                        |         |    |                        |
| Male/female      | 0.872   | 1.044 | 0.648–1.883           |         |    |                        |
| Age              |         |    |                        |         |    |                        |
| Per year         | 0.470   | 0.994 | 0.983–1.013           |         |    |                        |
| Tumor length     |         |    |                        |         |    |                        |
| Per cm           | 0.001   | 1.981 | 1.096–2.779           | 0.001   | 1.932 | 1.295–2.881           |
| Tumor number     |         |    |                        |         |    |                        |
| Multiple/single  | 0.171   | 1.460 | 0.783–2.370           |         |    |                        |
| BCLC             |         |    |                        |         |    |                        |
| B/A              | 0.526   | 1.193 | 0.598–1.890           |         |    |                        |
| C/A              | 0.039   | 1.594 | 0.927–2.254           |         |    |                        |
| Child–Pugh       |         |    |                        |         |    |                        |
| B/A              | 0.169   | 0.717 | 0.450–1.163           |         |    |                        |
| AFP              |         |    |                        |         |    |                        |
| > 400 ng/ml/ ≤ 400 ng/ml | 0.112 | 1.312 | 0.812–1.823 |         |    |                        |
| Edmondson-steiner|         |    |                        |         |    |                        |
| IV/III/II/I      | 0.323   | 1.099 | 0.830–1.204           |         |    |                        |
| Necrosis         |         |    |                        |         |    |                        |
| Yes/no           | 0.443   | 0.854 | 0.513–1.175           |         |    |                        |
| Local invasion   |         |    |                        |         |    |                        |
| Yes/no           | 0.078   | 1.363 | 0.929–1.864           |         |    |                        |
| ALB              |         |    |                        |         |    |                        |
| Per g            | 0.312   | 0.982 | 0.944–1.017           |         |    |                        |
| ALT              |         |    |                        |         |    |                        |
| Per U            | 0.165   | 0.995 | 0.989–1.002           |         |    |                        |
| AST              |         |    |                        |         |    |                        |
| Per U            | 0.224   | 1.002 | 0.998–1.006           |         |    |                        |
| ALP              |         |    |                        |         |    |                        |
| Per U            | 0.965   | 1.000 | 0.998–1.002           |         |    |                        |
| GGT              |         |    |                        |         |    |                        |
| Per U            | 0.001   | 1.004 | 1.002–1.006           | <0.001  | 1.003 | 1.002–1.005           |
| HBsAg            |         |    |                        |         |    |                        |
| Yes/no           | 0.468   | 0.826 | 0.408–1.162           | <0.001  | 1.643 | 1.181–2.285           |
| Times of HIO     |         |    |                        |         |    |                        |
| 1/0              | 0.007   | 1.659 | 1.158–2.405           | 0.003   | 1.643 | 1.181–2.285           |
| 2/0              | 0.001   | 2.604 | 1.505–4.491           | <0.001  | 2.501 | 1.521–4.112           |
| Blood loss       |         |    |                        |         |    |                        |
| > 400 ml/ ≤ 400 ml | 0.003 | 1.454 | 1.092–1.626           | 0.082   | 1.276 | 0.926–1.427           |

BCLC, Barcelona Clinic Liver Cancer; AFP, alpha fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; HIO, hepatic inflow occlusion.
Due to some selection or confounding bias, we also included all patient data in the multivariate Cox regression model, and the results showed that two times HIO was an independent risk factor affecting the postoperative OS of patients; HIO was an independent risk factor affecting the postoperative RFS of patients. In summary, our results suggest that HIO can affect the postoperative prognosis of ruptured HCC patients, but different blockage times will also affect the prognosis of patients differently.

This study has some limitations, namely: (1) This study is a retrospective study with some biases, and it is possible to perform a prospective study in the future to verify the conclusion. (2) The number of patients with ruptured HCC is relatively small, and the number of cases needs to be accumulated (3). Whether HIO affects postoperative complications has not been fully assessed, we need further investigation and follow-up.

In conclusion, HIO may affect the prognosis of patients with ruptured HCC, and the number of occlusion times can also affect the patients’ prognosis. Although further RCTs are needed to validate this conclusion, in practical clinical work, we should consider the impact that HIO brings to patients with rHCC.

**Abbreviations**

BCLC: Barcelona Clinic Liver Cancer; HIO: Hepatic inflow occlusion (HIO); HBsAg: Hepatitis B surface antigen; AFP: Alpha-fetoprotein; HCC: Hepatocellular carcinoma; HCC: Ruptured hepatocellular carcinoma; CT: Computed tomography; MRI: Magnetic resonance imaging; RFA: Radiofrequency ablation; TACE: Transcatheter arterial chemoembolization; OS: Overall survival; RFS: Recurrence-free survival; VVI: Microvascular invasion; ALB: Albumin; ALT: Alanine aminotransferase; AST: Aspartate Transaminase; ALP: Alkaline phosphatase; GGT: Glutamyl transpeptidase.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

FX wrote the paper. PZ and ZH provided the cases. PZ and MZ provided the medical images and interpretation of the data. BZ provided pathological images and interpretation of the data. PZ, XC, and EN reviewed and edited the manuscript. All authors read and approved the manuscript.

**Funding**

The research is funded by: (1) Natural Science Foundation of Hubei Province [2019CFB433]; (2) Hengrui Hepatobiliary and Pancreatic Malignant Tumor Research Fund-Youth Research Fund [CXPJH11800001-2018306]; (3) Sources of funding: Key project of science and technology in Hubei Province [2018ACA137]; (4) General Project of Health Commission of Hubei Province [WJ2021M108]. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Availability of data and materials**

The datasets used and analyzed in this study are available and can be obtained from the corresponding author on reasonable request.

**Declarations**

**Ethics and consent to participate**

This research was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology. All patients gave informed consent. The patients’ clinical and imaging information is the patients’ private data, and it is protected by Chinese laws. Therefore, the data and materials cannot be uploaded and shared with the public.

**Consent for publication**

Written informed consent for publication was obtained from the patients and/or their legal guardians for publication.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Center for Hepatic Surgery, Institute of HBP Surgery, Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Jiefang Avenue, Wuhan 1095, Hubei, China. 2 Department of Digestive Medicine Tongji Hospital of Tongji Medical College in Huazhong University of Science and Technology, Wuhan, Hubei, China.

Received: 16 December 2021 Accepted: 28 February 2022

**References**

1. Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.
2. Court T, Pillai A. Goals and targets for personalized therapy for HCC: Hep Int. 2019;13(2):125–37.
3. Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current state of liver-directed therapies and combinatorial approaches with systemic therapy in hepatocellular carcinoma (HCC). Cancers. 2019;11(8):1085.
4. Baskiran A, Akbulut S, Sahin TT, Koc C, Karakas S, Ince Y, Yurdakul C, Yilmaz S. Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. Hep Int. 2020;14(5):869–80.
5. Akbulut S, Koc C. Do we need to be limited by matching milan criteria for survival in living donor liver transplantation? J Gastrointest Cancer. 2020;S114:1107–13.
6. Sahu SK, Chawla YK, Dhiman RK, Singh V, Duseja A, Taneja S, Kalra N, Gorsi U. Rupture of hepatocellular carcinoma: a review of literature. J Clin Exp Hepatol. 2019;9(2):245–56.
7. Yoshida H, Mamada Y, Taniak N, Uchida E. Spontaneous ruptured hepatocellular carcinoma. Hepatol Res. 2016;46(1):13–21.
8. Abdalla BK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? Surg Clin North Am. 2004;84(2):563–85.
9. Dixon E, Vollmer CM Jr, Barie OF, Sutherland F. Vascular occlusion to decrease blood loss during hepatic resection. Am J Surg. 2005;190(1):73–86.
10. Tranchart H, O’Rourke N, Van Dam R, Gaillard M, Lainas P, Sugioaka A, Wakabayashi G, Dagher I. Bleeding control during laparoscopic liver resection: a review of literature. J Hepatobiliary Pancreat Sci. 2015;22(5):371–8.
11. Lei DX, Peng CH, Peng SY, Jiang X, Wu YL, Shen HW. Safe upper limit of hepatic microcirculatory dysfunction and irreversible hepatocyte injury in rats. Sci Adv Med Biol. 2015;7(1):713–7.
12. Li CH, Chen YW, Chen YL, Yao LB, Ge XL, Pan K, Zhang AQ, Dong JH. Preventing low perfusion during surgical liver blood inflow control prevents hepatic microcirculatory dysfunction and irreversible hepatocyte injury in rats. Sci Rep. 2015;5:14406.
13. van Reel WG, van Golen RF, Reiners MJ, Heger M, van Gulik TM. How much ischemia can the liver tolerate during resection? Hepatobiliary Surg Nutr. 2016;5(1):58–71.
14. Jiang JH, Wang JX, Zhu JY, Yang PP, Guo Z, Ma SL, Lu Y, Xiang BD, Zhong JH, Li LQ. Comparison of hepatectomy with or without hepatic inflow
occlusion in patients with hepatocellular carcinoma: a single-center experience. Minerva Med. 2017;108(4):324–33.
15. Chau GY, Lui WT, King KL, Wu CW. Evaluation of effect of hepatic vascular occlusion and the Pringle maneuver during hepatic resection for patients with hepatocellular carcinoma and impaired liver function. World J Surg. 2005;29(11):1374–83.
16. van Gulik TM, de Graaf W, Dinant S, Busch OR, Gouma DJ. Vascular occlusion techniques during liver resection. Dig Surg. 2007;24(4):274–81.
17. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
18. Xu X, Chen C, Liu Q, Huang X. A meta-analysis of TAE/TACE versus emergency surgery in the treatment of ruptured HCC. Cardiovasc Intervent Radiol. 2020;43(9):1263–76.
19. Zhang W, Zhang ZW, Zhang BX, Huang ZY, Zhang WG, Liang HF, Chen XP. Outcomes and prognostic factors of spontaneously ruptured hepatocellular carcinoma. J Gastrointest Surg. 2019;23(9):1786–800.
20. Zou J, Li C, Chen Y, Chen R, Xue T, Xie X, Zhang L, Ren Z. Retrospective analysis of transcatheter arterial chemoembolization treatment for spontaneously ruptured hepatocellular carcinoma. Oncol Lett. 2019;18(6):6423–30.
21. Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev. 2009;1:CD007632.
22. Suzuki S, Inaba K, Konno H. Ischemic preconditioning in hepatic ischemia and reperfusion. Curr Opin Organ Transplant. 2008;13(2):142–7.
23. Wang HQ, Yang JY, Yan LN. Hemihpetic versus total hepatic inflow occlusion during hepatectomy: a systematic review and meta-analysis. World J Gastroenterol. 2011;17(26):3158–64.
24. Li M, Zhang T, Wang L, Li B, Ding Y, Zhang C, He S, Yang Z. Selective hepatic vascular occlusion versus pringle maneuver in hepatectomy for primary liver cancer. Med Sci Monitor. 2017;23:2203–10.
25. Zhang Y, Yang H, Deng X, Chen Y, Zhu S, Kai C. Intermittent Pringle maneuver versus continuous hemihpetic vascular inflow occlusion using extra-glissonian approach in laparoscopic liver resection. Surg Endosc. 2016;30(3):961–70.
26. Huang J, Tang W, Hernandez-Alejandro R, Bertens KA, Wu H, Liao M, Li J, Zeng Y. Intermittent hepatic inflow occlusion during partial hepatectomy for hepatocellular carcinoma does not shorten overall survival or increase the likelihood of tumor recurrence. Medicine. 2014;93(28):e288.
27. Lan X, Li H, Liu F, Li B, Wei Y, Zhang H, Xu H. Does liver cirrhosis have an impact on the results of different hepatic inflow occlusion methods in laparoscopic liver resection? a propensity score analysis. HPB (Oxford). 2019;21(5):531–8.
28. Wei X, Zheng W, Yang Z, Liu H, Tang T, Li X, Liu X. Effect of the intermittent Pringle maneuver on liver damage after hepatectomy: a retrospective cohort study. World J Surg Oncol. 2019;17(1):142.
29. Xu W, Xu H, Yang H, Liao W, Ge P, Ren J, Sang X, Lu X, Zhong S, Mao Y. Continuous Pringle maneuver does not affect outcomes of patients with hepatocellular carcinoma after curative resection. Asia Pac J Clin Oncol. 2017;13(5):e321–30.
30. Jiménez-Castro MB, Cornide-Petronio ME, Gracia-Sancho J, Peralta C. Inflammomosome-mediated inflammation in liver ischemia-reperfusion injury. Cells. 2019;8(10):1131.
31. Saidi RF, Kenari SK. Liver ischemia/reperfusion injury: an overview. J Investigative Surg. 2014;27(6):366–79.
32. Cotterell AH, Fisher RA. Ischemia/reperfusion injury and hepatocellular carcinoma recurrence after liver transplantation: cancer at WIT’s End? Dig Dis Sci. 2015;60(9):2579–80.
33. Grąt M, Krawczyk M, Wronka NM, Stypułkowski J, Lewandowski Z, Wasilewicz M, Krawczyk P, Grąt K, Patkowski W, Żeniarczyk K. Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation. Sci Rep. 2018;8(1):8935.
34. Man K, Ng KT, Lo CM, Ho JW, Sun BS, Sun CK, Lee TK, Poon RT, Fan ST. Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases–activation of cell invasion and migration pathways. Liver Transplant. 2007;13(12):1669–77.
35. Theodorakis K, Papadopoulou M, Metropoulou Z, Theodosopoulou T, Vassilou P, Polydorou A, Xanthakos P, Fragulidis G, Smyrniotis V, Arkadopoulos N. Does vascular occlusion in liver resections predispose to recurrence of malignancy in the liver remnant due to ischemia/reperfusion injury? A comparative retrospective cohort study. Int J Surgery (London, England). 2020;80:68–73.
36. Shen L, Uz Z, Verheij J, Veelo DP, Ince Y, Ince C, van Gulik TM. Interpatient heterogeneity in hepatic microvascular blood flow during vascular inflow occlusion (Pringle manoeuvre). Hepatobiliary Surg Nutr. 2020;9(3):271–83.
37. Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured hepatocellular carcinoma: current status of research. Front Oncol. 2022;12:848903.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.